<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MM22RPD" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
Open Mobile Menu
rows
Home
chevronright
chevronleft
Products
chevronright
Current Page
INVOKAMET®
(canagliflozin-metformin HCl)
Search INVOKAMET...
Search
search
INVOKAMET® (canagliflozin-metformin HCl)
icon-pdf
Full Prescribing Information including BOXED WARNING (English)
icon-pdf
Full Prescribing Information including BOXED WARNING (Spanish)
icon-pdf
Medication Guide (English)
icon-pdf
Medication Guide (Spanish)
icon-resources-med-search
Search Medical Information
icon-resources-links
Useful Links
Clinical Trial Publications
Chronic Kidney Disease/Heart Failure
CREDENCE
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med
. 2019;380(24):2295-2306
Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.
Circulation.
2019;140(9):739-750
Cardiovascular Events
CANVAS Program
Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
N Engl J Med.
2017;377(7):644-657.
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Circulation.
2018;137(4):323-334.
Glycemic Control
CANVAS Program
Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
N Engl J Med.
2017;377(7):644-657
Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Diabetes Obes Metab.
2013;15(4):372-382.